outlook earn preview
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
report earn feb press releas call et call
number use chart shown review section includ share trade
head into/out earn histor case dont time dens text feel free
skim
gener outlook remain share given signific concern around
epacadostat abil show benefit beyond keytruda random control phase
trial set read year though share weak recent month investor
sentiment sour littl epacadostat chanc though still remain surprisingli optimist
believ current valuat still requir confid ido clock jakafi patent expiri start
tick soon epacadostat fail may face difficult choic scale
 off-set eventu patent cliff versu drive toward profit sustain near-term
investor interest compani interesting/cr approach tri deliv life
jakafi mf beyond time tell effort bear suffici fruit off-set eventu loss
blockbust franchis
nv alreadi report olumi ou jakavi revenu
investor sentiment gener bullish although confid epacadostat continu erod overal
mani investor still either believ epacadostat either like work els good risk-reward
data limit fundament downsid cautiou downsid share
epacadostat fail difficult gaug combin uncertain trial outlook wait see
event transpir cours year
model updat revis pt
increas spend estim align consensu
slightli adjust jakafi estim reflect potenti slight inventori draw-down
lower termin growth reflect fact compani final year
jakafi exclus model end lack confid epacadostat
succeed creat meaning termin valu
focal point
guidanc like call mid-februari
epacadostat phase melanoma
baricitinib adcom potenti approv us pdufa estim around mid-year eu
top-line phase readout acut gvhd along progress label
fgfr inhibitor cholangiocarcinoma
pipelin evolution/contribut posit new antibodi
head investor attent focus epcadostat inci wholly-own ido inhibitor
top-line result phase studi melanoma evalu epcadostat
keytruda vs keytruda alon latest investor survey note optim wane sinc
esmo mani still bullish potenti ido melanoma solid tumor
well note comprehens phase program underway multipl solid tumor bladder
kidney head neck etc continu remain wari still dont fulli understand scienc
convinc benefit seen studi better could achiev
antibodi alon baselin characterist match particular high number
statu indetermin believ may indic earlier stage patient higher
respons rate vs histor compar trial opdivo keytruda furthermor recent
data call question util predict biomark tumor mutat burden
emerg independ highli predict metric respons
minor updat year exist epacadostat phase studi
investor focu also baricitinib partner follow last year up down
approv prospect recent sign bullish eu launch exceed intern
expect resubmiss fda complet earli decemb guidanc end
januari well phase trial atop dermat underway commentari
phase lupu data also encourag data come medic confer possibl eular
acr expect adcom date post yet
view key success differenti jak class approv high dose
 mg dose xeljanz vs mg dose mg dose vs mg dose
eu launch progress well compani commentari indic launch
intern forecast outperform ra drug launch germani
ultim may struggl crowd jak inhibitor field includ well
tax reform realiti us major beneficiari thu expect
mid low tax rate though note consensu seem alreadi reflect tax rate
neighborhood note emerg pipelin asset epacadostat fgfr delta
inhibitor ex-u domicil emerg long term impact tax rate may
need re-evalu
commerci front jakafi continu outperform new patient addit high
persist eventu label expans gvhd essenti thrombocytosi also continu
drive jakafi outer year number higher least patent expiri expect guidanc
announc earn call mid-februari consist prior practic note
took price increas dec gener consist previou practic price increas per
next major data readout jakafi studi evalu
acut steroid refractori gvhd patient singl arm studi run us
believ potenti elig patient thu could repres
increment hundr million addit revenu although durat therapi
somewhat unclear goal wean patient steroid first jakafi
gener optimist potenti success given case report larg multi-
center retrospect analysi indic orr chronic acut gvhd
set cr acut set
said orr would clinic meaning higher may
expect steroid alon durabl effect need establish
compani start explor combo transit regimen mf effort extend
presenc field beyond patent expiri jakafi includ number
combo/transit studi includ itacitinib mani get start
late year expect data select inhibitor patient
cholangiocarcinoma transloc acceler previou timelin
expect continu enrol variou basket fight program
one asset mani investor radar screen capmatinib select c-met inhibitor encourag
data patient driver mutat nsclc opportun similar market nv
control develop entitl world-wide royalti retain co-develop
co-promot option nv signal expect data later year uncontrol studi
nsclc patient high c-met express tumor intend file approv prior
in-licens world-wide right mgnx antibodi up-front
potenti regulatori develop mileston commerci mileston
royalti perhap surpris given safeti signal previou antibodi licens
hengrui expect detail focu clinic develop strategi inci
commentari indic prefer control clinic develop inhibitor
combin emerg pipelin i/o mechan gitr etc provid
flexibl speed also enabl go indic may left behind
unexplor roch other
behind asset emerg pipelin includ inhibitor pivot
citadel phase program b-cell malign face emerg competit threat car-t
btk inhibitor attract mechan pim brd gitr cancer mechan
develop far none jump page particularli compel
think earn earn cours year follow chart highlight
product specif perform past quarter red miss green beat blue in-lin
despit jakafi guidanc revis mani time throughout year product continu
outperform nv report sale suggest row royalti meet consensu
also includ estim along consensu
track guidanc detail past quarter along consensu
expect compar number note continu growth jakafi off-set
high level spend roughli break-even profit expect
here share trade histor around quarter left column nbi adjust red
mean trade green mean trade blue move compani gener
jakafi incom ep compani report evr isi analyst evr isijakafi guidanceno guidanceno guidancemilestonesup fair ex-up non-sourc compani report evr isi analyst commentaryannu revenu guidanc unless indic quarter februari
here matter key line item cours
here product-level perform commentari prior quarter
pre-earn post-earn nbi pre-earn pre-earn post-earn nbi pre-earn pre-earn post-earn nbi pre-earn post-earningsproduct/lin itemfocuscommentjakafi revenuescontinu uptak mf pv enrol et trial next leg growthjakafi beat rais stori continu uptak jakafi pv provid continu growth recent took price increas decemb ou revenuescontinu uptak mf pv partner nvsproduct gener met consensu prior quartersbaricitinibpartn discuss fda chang allow resubmiss nda new data includ packag resubmit ahead schedul commentari bullish increment benefit mg mg mg like requir commerci success differenti fieldepacadostatprimari focu us street compar checkpoint studi commerci potenti trial initi new tumor typeswhat might expect checkpoint inhibitor alon patient properli match studi baselin criteria pipelin driversminim focu street program beyond epacadostatwhil program interest program earli unlik meaning upsid driversr spendvari given partnership ramp clinic programsposs lever continu earn growth though addit epacadostat phase studi underway may difficult curtail compani report evr isi analyst commentaryinci area focu upcom earn februari
roll commentari around pipelin last year along latest updat post
line net patient growth jakafitot patient growth sinc includ jakafi recommend treatment pvcontinu growth pv mflong term net product revenu guidanc mf pv gvhd long term inventoryannu guidanc updaterais guidancerais guidancepric expansionet trial udnerway reset epacadostat ido inhibitor expand addit phase studi ye combin keytrudaupd data esmo data expect melanoma phase trial underway combin epacadostat across collabor initi yebaricitinibapprov eu us review time extend mocrl issu fda receiv japanes approv commentari us mo minimum resubmiss time us addit clinic studiessubmiss complet end jan class ii resubmiss mo review success adjakaficommentaryinci histor perform commentari februari
program target et begin pivot studi et open enrol includ long-term pivot studi et underwaymultipl jak combo underway mf itacitinib pim brd may see data underway begin initi data snda submiss steroid refractori agvhd data snda submiss initi data snda submiss pivot primari endpoint orr secondari durabl look rrtopic jakafi atop dermat recent initi vitiligo begin jakafi atop dermat vitiligo initi june ongoingtop jakafi atop dermat vitiligo initi june ongoingphas enrol complet sitesphas data melanoma expect fulli enrol data data melanoma expect data melanoma expect indic begin updat data multipl tumor type present nsclc renal bladder head neck begin ye phase additon pivot start renal/lung studi pembro clinicaltri govphas updat data multipl tumor type present nsclc renal bladder head neck begin ye phase studi run variou solid tumor across collaborationexpand collabor includ tumor type nsclc head neck expand collabor includ tumor type nsclc head neck rcc epa/pembro vs sutent votrient high nsclc epa/pembro vs pembro nsclc vs pembro platinum doublet vs epa/pembro coprimari pfs/osexpand collabor includ tumor type nsclc head neck phase expans cohort combin durvalumabphas expans cohort combin durvalumabexpans program azn durvalumab start nsclc share cost studi begin popul pacificphas expans cohort combin durvalumabphas expans cohort combin durvalumabphas dose-escal on-going combin atezolizumab dose-escal on-going combin atezolizumab dose-escal on-going combin atezolizumab fdaapprov japan ra submiss time us expect ot mo minimumlli resubmit januari class ii resubmiss mo includ new safeti efficacyapprov japan ra submiss time us expect ot mo minimumresubmiss complet decemb class ii resubmissionatop dermat sle phase dermat sle phase report posit data ad sleatop dermat sle phase proceed phase ad sle phase releas medic enrollingphas enrollingcitadel open dlbcl fl mzl mcl respectivelyphas enrollingdata dose escal combin tagrissophas dose escal combin tagrissophas dose escal combin tagrissopivot program begin develop treatment nave acut gvhd gravita underway nave acut gvhd combin steroid vs pbo gravita underwayphas gravita underway nave acut gvhd combin steroid vs pbo phase combin pair biopsi studi on-going combin dose escalationphas dose escalationphas dose escalationevalu aml data combin ido combin ido combin ido nsclc met amplif mutat nv anticip submit nda c-met data nsclc file enter proof concept trial dose escalationphas dose fgfr phase trial data present call trial underway open fight bladder cholangio mpn recruit wellphas trial underway cholangiocarcinoma data bladder escal complet enrol suspendeddos escal complet enrol suspendedannounc new collabor mdgx alreadi clinic combin portfoliodos escal complet enrol suspendedlicens deal mgnxphase dose escal underway gitr dose escal underway gitr complet dose escal combo cohort underwayphas dose escal underway gitr phase dose escal underway partner argi dose escal on-going evalu phase dose escal underway partner phase dose escal brd priorizit data rest dose escalationfirst man brd pim data expect brd priorizit data rest dose escalationsourc compani report evr isi analyst commentaryinci pipelin commentaryotherbaricitinibepacadostat ido jakafiitacitinib februari
biotech comp tabl although rate share would remiss note
among select biotech compani market cap ep project deliv ep
compound-annual-growth-rate trifecta achiev pcyc mdvn prior acquisit
n/m last n/a factset tax adjust adjust reflect sni jvev mm comparison metric larg cap biotechcompanymkt cap mm consensu ptcurrent priceconsensu rate buy sell average analyst pt vs currentlast performancelast performancefcf yielddividend yieldavg ep beat last quarter ep beat last quartersshort intereststock perform vs nbi absolut price-to-earnings estimatesr salescomparison metric larg cap biotechcompanyprice/ earn ad year ep compound-annual-growth-rate estim year ep compound-annual-growth-rate estimatesep yr compound-annual-growth-rate deltap/e/gev/fcfev/ebitdaro februari
last last factset tax adjustedev/fcfev/ebitdaroicstock perform vs nbi absolut price-to-earnings estimatesr salescomparison metric pharmacompanyprice/ earn ad year ep compound-annual-growth-rate estim year ep compound-annual-growth-rate estimatesep yr compound-annual-growth-rate deltap/e/gconsensu ptcurrent priceconsensu rate buy sell average analyst pt vs currentlast performancelast performancefcf yielddividend yieldshort interestev mm comparison metric pharmacompanymkt cap mm februari
patient treat jakafi
therapi rebat estimate
number treat jakafi
therapi rebat estimate
pv pt treat jakafi
therapi rebat estimate
et pt treat jakafi
jakafi royalti rate nv
royalti revenu nv
royalti revenu
compani report evr isi analyst estim
good sold
interest incom expens
loss debt redemption/oth
compani report evr isi analyst estim
valuat basi pt base dcf use discount rate appli
commerci stage biotech compani termin growth rate equat termin multipl compar
compani deliv ep compound-annual-growth-rate addit year compound-annual-growth-rate addit year jakafi
generic like toward latter half next decad believ reason termin growth assumpt
includ contribut jakafi et gvhd well eventu launch olumi model
contribut epacadostat specif howev includ meaning gener catch-al line item reach
captur program ido inhibitor fgfr inhibitor inhibitor
risk upsid risk in-lin rate includ better-than-expect perform jakafi includ success et
gvhd believ drive share around quarterli earn pipelin program success epacadostat
compound rapid margin expans optim cash flow jakafi abil find near-term path forward
olumi downsid risk in-lin rate includ failur epacadostat pipelin program increas competit
threat and/or delay olumi continu aggress develop spend jakafi patent expiri draw near caus
investor concern regard valuat
articl articl
time dissemin februari et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu primarili respons prepar
research report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
